{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:18:34Z","timestamp":1783448314618,"version":"3.55.0"},"reference-count":24,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":165,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>Poor outcomes in pancreatic neuroendocrine neoplasms (pNENs) partially result from the inability to identify early-stage disease in patients. Prevention strategies have focused on identifying high-risk patients through genetic susceptibility genes. This study aims to report the incidence of pathogenic germline variants (PGVs) in pNEN. 129 pNEN patients that underwent germline testing with Invitae between September 5, 2019, and February 15, 2022, were retrospectively analyzed. PGVs were found in 14.7% (19\/129) of pNENs. PGVs in pancreatitis genes were detected in 7.7% (3\/39) of the 39 pNEN patients with an available pancreatitis panel. CFTR alterations were the most common pancreatitis-associated gene identified (5.1%, 2\/39). MUTYH alterations were the most frequently detected (3.9%, 5\/129) PGV in pNENs. DNA or base repair PGVs were found in 7.8% (10\/129). Our findings suggest that germline testing may play a role in the standard-of-care management of pNEN. MUTYH alterations merit further evaluation as a potential risk factor for pNEN.<\/jats:p>","DOI":"10.1530\/eo-25-0088","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:49:23Z","timestamp":1779101363000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":0,"title":["Pathogenic germline variants identified in pNEN patients during genetic testing"],"prefix":"10.1530","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8310-1997","authenticated-orcid":true,"given":"Tara","family":"Arouchian","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gangi","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Wing","family":"Fung","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Dumitra","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrahm","family":"Levi","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsen","family":"Osipov","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E","family":"Hendifar","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026070713573800000_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"2026070713573800000_bib2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/oncolo\/oyac049","article-title":"Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis","volume":"27","author":"Sonbol","year":"2022","journal-title":"Oncologist"},{"key":"2026070713573800000_bib3","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40618-022-01985-2","article-title":"The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States","volume":"46","author":"Liu","year":"2023","journal-title":"J Endocrinol Investig"},{"key":"2026070713573800000_bib4","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.2147\/CMAR.S174907","article-title":"Prognosis of patients with neuroendocrine tumor: a SEER database analysis","volume":"10","author":"Man","year":"2018","journal-title":"Cancer Manag Res"},{"key":"2026070713573800000_bib5","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","article-title":"Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival","volume":"19","author":"Halfdanarson","year":"2008","journal-title":"Ann Oncol"},{"key":"2026070713573800000_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.21037\/jgo.2020.03.09","article-title":"Inherited syndromes involving pancreatic neuroendocrine tumors","volume":"11","author":"Geurts","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"2026070713573800000_bib7","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/2159-8290.CD-21-0669","article-title":"Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system","volume":"12","author":"Yachida","year":"2022","journal-title":"Cancer Discov"},{"key":"2026070713573800000_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"key":"2026070713573800000_bib9","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0057","article-title":"Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"30","author":"Venizelos","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2026070713573800000_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1158\/1940-6207.CAPR-23-0483","article-title":"Germline testing identifies pathogenic\/likely pathogenic variants in patients with pancreatic neuroendocrine tumors","volume":"17","author":"Mohindroo","year":"2024","journal-title":"Cancer Prev Res"},{"key":"2026070713573800000_bib11","article-title":"Real-time genomic characterization of metastatic pancreatic neuroendocrine tumors has prognostic implications and identifies potential germline actionability","volume":"2018","author":"Raj","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2026070713573800000_bib12","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/gut.2005.074534","article-title":"Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma","volume":"54","author":"McWilliams","year":"2005","journal-title":"Gut"},{"key":"2026070713573800000_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251356335","article-title":"Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study","volume":"17","author":"Riechelmann","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"2026070713573800000_bib14","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1038\/s41467-022-31341-0","article-title":"Inherited MUTYH mutations cause elevated somatic mutation rates and distinctive mutational signatures in normal human cells","volume":"13","author":"Robinson","year":"2022","journal-title":"Nat Commun"},{"key":"2026070713573800000_bib15","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.hpb.2024.05.005","article-title":"High frequency of germline variants in CFTR identified in PDAC patients enrolled in an expanded panel multi-gene panel testing program","volume":"26","author":"Hendifar","year":"2024","journal-title":"HPB"},{"key":"2026070713573800000_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-025-04296-y","article-title":"Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping","volume":"488","author":"Kasajima","year":"2026","journal-title":"Virchows Arch"},{"key":"2026070713573800000_bib17","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.3390\/ijms22084041","article-title":"Pancreatic neuroendocrine neoplasms in multiple endocrine neoplasia type 1","volume":"22","author":"Marini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026070713573800000_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41698-025-01210-2","article-title":"CDKN2A homozygous deletions and TSC2 somatic mutations in metastatic pancreatic neuroendocrine tumors","volume":"10","author":"Jesus","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026070713573800000_bib19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00018-023-05084-0","article-title":"FOXA2-initiated transcriptional activation of INHBA induced by methylmalonic acid promotes pancreatic neuroendocrine neoplasm progression","volume":"81","author":"Hu","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"2026070713573800000_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.gendis.2017.01.003","article-title":"HOXB13 mutations and binding partners in prostate development and cancer: function, clinical significance, and future directions","volume":"4","author":"Brechka","year":"2017","journal-title":"Genes Dis"},{"key":"2026070713573800000_bib21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3390\/cancers11050734","article-title":"Deciphering the potential role of hox genes in pancreatic cancer","volume":"11","author":"Kuo","year":"2019","journal-title":"Cancers"},{"key":"2026070713573800000_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0304-3835(03)00456-7","article-title":"RET and neuroendocrine tumors","volume":"204","author":"Ichihara","year":"2004","journal-title":"Cancer Lett"},{"key":"2026070713573800000_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103882","article-title":"Targeting Ret alterations in cancer: recent progress and future directions","volume":"181","author":"Shabbir","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026070713573800000_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105543","article-title":"BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation\/expansion multicenter study","volume":"10","author":"Sch\u00f6ffski","year":"2025","journal-title":"ESMO Open"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/6\/1\/EO-25-0088.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/6\/1\/EO-25-0088.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0088\/505324\/eo-25-0088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0088\/505324\/eo-25-0088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:58:16Z","timestamp":1783447096000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/6\/1\/e250088\/75479\/Pathogenic-germline-variants-identified-in-pNEN"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-25-0088","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"e250088"}}